PTH is a major regulator of calcium homeostasis by mobilizing calcium through bone resorption. We show that the expression of collagenase-3 (MMP-13), a member of the family of matrix metalloproteinases, required for the cleavage of collagens in the bone, is increased upon PTH injection in mice. A cis-acting element in the collagenase-3 promoter was identi®ed which, together with AP-1, is required for induction by PTH. This element contains CCACA motifs which are required for binding of the 65 kDa osteoblast-speci®c splice variant of Cbfa1. Introduction of mutations in this binding site that interfere with protein interaction also eliminates PTH inducibilty and transactivation by Cbfa/ Runt proteins. While DNA binding activity of AP-1 is increased upon PTH treatment, high basal level of Cbfa/ Runt binding activity is detectable in untreated cells which is not further increased by PTH, suggesting that AP-1 and Cbfa1 contribute to transcriptional activation through dierent mechanisms. In agreement with the critical role of both proteins de®ned in tissue culture cells, expression of collagenase-3 is reduced in mice lacking c-fos and is completely absent in cbfa1 7/7 embryos. These data provide the ®rst evidence for a critical role of Cbfa1, a major regulator of bone development, in PTH-dependent processes such as bone resorption.
Introduction
Parathyroid hormone (PTH) is a major regulator of Ca 2+ homeostasis. Secreted by the parathyroid gland it stimulates release of calcium and phosphate from bone, the main calcium store in the body. The action of PTH in bone is rather complex and still poorly understood. At high concentrations it acts as a bone resorbing hormone inducing the release of calcium and of matrix components such as collagen. It is also responsible for inhibiting bone collagen and matrix synthesis. On the other hand, at intermittent administration of low doses, anabolic eects of PTH have been described which lead to an increase in the formation of trabecular bone (Kronenberg, 1996) . PTH and the second member of the PTH family, the PTH-related peptide (PTHrP), bind with equivalent anities to a common G protein-linked receptor (Juppner et al., 1991) . The receptor, as well as the ligands, are expressed during embryogenesis in areas of cartilage and bone formation. Analysis of knockout mice has already revealed a critical role for PTH/PTHrP and their receptor signalling in bone growth and development (Karaplis et al., 1994; Lanske et al., 1996) . Intracellular signalling initiated by the ligand-activated PTH/PTHrP receptor is mediated predominantly by activation of adenylate cyclase resulting in enhanced concentrations of cAMP and activation of PKA (Evans et al., 1996; Yang and Gerstenfeld, 1996) . Overexpression of a constitutively active mutant of the receptor leads to accumulation of ligand-independent levels of cAMP (Schipani et al., 1995) . In addition, activation of phospholipase C, leading to phosphatidylinositol cleavage and induction of PKC activity, has been described (Abou-Samra et al., 1989) . While the biological functions of PTH in vivo and the signalling pathways initiated by PTH are well established only a very limited number of PTH-regulated genes, including interstitial collagenase (Heath et al., 1984; Scott et al., 1992) , have been de®ned, in in vitro cultures of bone primary cells or in osteoblast-derived osteosarcoma cell lines.
Interstitial collagenase (collagenase-3, MMP-13) is a member of the large family of matrix metalloproteinases (MMPs) which play a decisive role in the degradation of the components of the extracellular matrix (ECM), particularly the collagens. It degrades collagen type II most eciently (Knauper et al., 1996) but also collagens type I, III and X which are the most abundant members of the collagen family and the major components of cartilage and bone. MMP-13 was ®rst characterized in mouse and rat (Henriet et al., 1992; Gack et al., 1994) and corresponds to the human homologue collagenase-3 which was isolated from breast carcinoma cells (Freije et al., 1994; Pendas et al., 1997) . During embryogenesis expression of MMP-13 in hypertrophic chondrocytes, osteoblasts and osteocytes Mattot et al., 1995) is thought to be responsible for the removal of collagen II from the cartilaginous bone primordium during endochondral ossi®cation. In the adult bone, MMP-13 is thought to be involved in bone remodelling. High constitutive levels of MMP-13 were observed in osteosarcomas and chondrosarcomas suggesting an important role for this enzyme in the formation of bone tumours Grigoriadis et al., 1995) .
The transcription factor AP-1, which is composed of members of the Jun, Fos and ATF families, has been found to be a major regulator of MMP-13 transcription in a large number of tissue culture cells in response to a broad spectrum of extracellular signals, such as growth factors, cytokines, tumour promoters, carcinogens, and oncogene products (Angel and Karin, 1991) . There is evidence that enhanced transcription and de novo synthesis of c-Jun and c-Fos are involved in PTHdependent induction of MMP-13 expression in osteosarcoma cell lines Rajakumar and Quinn, 1996) . However, the fact that ubiquitous overexpression of c-Fos in transgenic mice is accompanied by a tissue-speci®c enhancement of MMP-13, most dominantly in bone (Gack et al., 1994) , would suggest that, in addition to AP-1, other factors, most probably bone speci®c, may be instrumental in MMP-13 expression in vivo.
The data presented identify MMP-13 as a target gene of PTH-dependent signalling in mice. We have identi®ed the AP-1 site and another cis-acting element in the murine MMP-13 promoter which is highly homologous to the recently identi®ed osteoblastspeci®c element-2 (OSE-2) of the osteocalcin promoter to be required for the PTH response. In vitro binding studies, overexpression studies in transiently transfected cells and analysis of MMP-13 expression in cbfa1 knockout mice strongly suggest that the OSE-2 sequence is recognized by members of the Cbfa/Runt family of transcription factors. Exempli®ed by the regulation of the MMP-13 promoter, these data provide the ®rst evidence for a potential critical role of the osteoblast-speci®c factor Cbfa1, a major regulator of bone development (Ducy et al., 1997; Komori et al., 1997; Otto et al., 1997) , in PTHdependent processes such as bone resorption and Ca 2+ homeostasis.
Results
PTH is a potent inducer of MMP-13 transcription in vitro and in vivo MMP-13 expression is restricted mainly to the area of bone development and remodelling . It is reasonable to assume that hormones controlling bone metabolism, such as parathyroid hormone (PTH), are the main regulators of MMP-13 transcription in these tissues. In agreement with previous ®ndings (Heath et al., 1984; Scott et al., 1992) , PTH is a very potent inducer of MMP-13 mRNA expression in ROS 17/2.8 or UMR 106 rat osteosarcoma cells (Figure 1a ). This induction was stronger than that of the phorbol ester TPA, which has been shown to be the most ecient activator of interstitial collagenase expression in many primary and immortalized cells (Angel et al., 1987a; Angel and Karin, 1991) . Similar results were obtained in cell lines established from spontaneously occurring osteosarcomas in mice (data not shown). To con®rm PTH-dependent induction of MMP-13 in vivo, mice were injected with PTH in the vicinity of the calvaria and 8 h later RNA was prepared from isolated calvaria. As shown in Figure 1b , the levels of MMP-13 were greatly upregulated, demonstrating that MMP-13 mRNA expression is subject to PTH regulation in vivo. 78 M (PTH) or treated with 12-O-tetradecanoyl-phorbol-13-acetate at a concentration of 100 ng/ml (TPA). The cells were harvested after 4 h and the levels of MMP-13 transcripts were measured by Northern Blot analysis using 20 mg total RNA. The blot was ®rst hybridized with a 32 P labelled cDNA probe from the MMP-13 gene. Rehybridization using a cDNA fragment of GAPDH served as a control for equal loading and quality of the RNA. (b) Six month old male C57BL/6 mice were injected subcutaneously over the midline of the parietal bone with 0.9% NaCl (Control, Co) or 20 mg of 1 ± 34 fragment from rat PTH (PTH) dissolved in 0.9% NaCl. After 8 h, animals were sacri®ced, the calvaria was prepared and liberated from non-osseous tissues. Total RNA was prepared and the level of MMP-13 and b-actin transcripts were measured by RT ± PCR Using in situ hybridization analysis, enhanced expression could be localized to osteoblasts (data not shown). PTH inducibility was also observed in primary osteoblasts that were isolated from 10 day postnatal mice and cultured in vitro under conditions allowing osteoblast dierentiation (data not shown).
The AP-1 binding site and additional upstream elements are required for PTH-dependent activation of the MMP-13 promoter
To identify the promoter elements mediating the transcriptional induction of the MMP-13 gene by PTH, dierent fragments of the MMP-13 promoter (Schorpp et al., 1995) were fused to the CAT reporter gene. Constructs were introduced into ROS 17/2.8 osteosarcoma cells by transient transfection and the levels of CAT transcripts in untreated and PTH-treated cells were determined by RNase protection analysis. As shown in Figure 2 , the MMP-13 promoter fragment covering the region 7663 to +29 mediated very ecient activation by PTH. Similar to the regulation of the endogenous MMP-13 gene (Figure 1a) , PTH induced the MMP-13-CAT construct with higher eciency compared to TPA (Figure 2 , ®rst panel), suggesting that the promoter region from 7663 to +29 encodes all elements required for PTH-dependent MMP-13 expression. Likewise, similar results were observed using a promoter fragment from 7500 to +29 (data not shown). We next used an MMP-13 promoter construct spanning the region from 766 to +29. Based on in vivo footprinting analysis (Herr, Baumann and Angel, unpublished) and in vitro binding studies (Schorpp et al., 1995) only a high anity AP-1 binding site (747/741; 5'-TGACTCA-3') which is recognized by Fos/Jun heterodimers (Schorpp et al., 1995) is present in this fragment. This binding site was sucient to mediate inducibility by TPA, similar to the 7663/+29 promoter sequence (Figure 2 , second panel). In contrast, inducibility by PTH is almost completely lost suggesting that the AP-1 site by itself was not sucient for the PTH response seen, but that one or multiple cis-acting elements located between 7500 and 766 are required for induction. To analyse whether these elements mediate inducibility independently from the AP-1 site we fused the MMP-13 promoter fragment 7500/766 to the heterologous thymidine kinase (tk) promoter. Compared to the activity of the tk promoter, the 7500/766 fragment did not exhibit signi®cant basal activity (Figure 2 ). Similar to other cells (Angel et al., 1987a) , expression from the tk promoter was activated by TPA but was not dierent from the 7500/766 tk-CAT construct. PTH did not aect expression of either one of the plasmids. These data therefore show that (i) no additional TPA-responsive element is present in the 7500/766 region and (ii) that the PTH-responsive element(s) in this region are not active on their own but require the presence of the AP-1 site.
A binding site for members of the Cbfa/Runt transcription factor family mediates the PTH response in the MMP-13 promoter To search for known transcription factor binding sites that may be required for the PTH response, we compared the promoter sequence of the collagenase MMP-13 (Coll) and osteocalcin (OC) genes ( Figure  3a ). Similar to MMP-13, expression of the osteocalcin gene is restricted to cells of the osteoblastic lineage and is subjected to regulation by PTH (Yu and Chandrasekhar, 1997) . Most interestingly, in the osteocalcin promoter, osteoblast speci®c responsive elements (OSE) have been characterized, which are responsible for cell-type speci®c expression . One of these sites, OSE2 (7132/7127), shares a high degree of sequence homology to a region in the MMP-13 promoter from position 7139 to 7129. The sequence in the osteocalcin promoter is speci®cally recognized by a family of DNA binding proteins, namely the Cbfa/Runt proteins, also known as Polyoma Enhancer Binding Protein 2, PEBP2. The members of this family share a highly conserved 128 amino acid RUNT region responsible for DNA binding to the consensus sequence 5'-PuCCPuCA-3' (Kamachi et al., 1990) , which exhibit signi®cant Figure 2 Two independent regions in the MMP-13 promoter are required to mediate inducibility by PTH. ROS 17/2.8 osteosarcoma cells were transiently transfected with CAT reporter constructs whose expression was driven by dierent promoter fragments of the MMP-13 gene: 7663/+29 promoter fragment; 766/+29 promoter fragment; 7500/766 promoter fragment fused to the 7105/+56 promoter region of the thymidine kinase gene of Herpes Simplex Virus (tk); or the tk promoter alone. Transfected cells were left untreated (control, Co) or treated with TPA (100 ng/ml) or PTH (10 78 M). After 4 h, cells were harvested and RNA was prepared. The levels of CAT transcripts were determined by RNase protection analysis. The riboprobe covering a 298 bp EcoRI/PvuII fragment of the tk-CAT reporter plasmid (pBLCAT2) generates RNase-protected fragments of 210, 207 and 205 nucleotides after hybridization to tk-CAT transcripts initiated at the three start sites of transcription in the tk promoter (Angel et al., 1987b) . The probe generates a 150 nucleotide protected fragment after hybridization to the MMP-13-CAT transcript corresponding to the region of identity between the Tk-CAT and MMP-13-CAT genes sequence homology to the RUNT protein of Drosophila (Ogawa et al., 1993a) .
To analyse whether the region 7139/7129 of the MMP-13 promoter, containing two adjacent CCACA motives, serves as a binding site for members of the Cbfa/Runt family we compared the electrophoretic mobility of protein/DNA complexes formed in vitro with MMP-13 (OSE-Coll) and osteocalcin (OSE-OC) sequences. As shown in Figure 3b , one speci®c complex (CI) is obtained with OSE-OC (lanes 5 and 13). When using OSE-Coll, two speci®c complexes, CI and CII, with dierent mobilities are obtained (lanes 1 and 9). The electrophoretic mobility of CI, using OSE-Coll, is very similar to CI of OSE-OC. In addition, a slower migrating complex, CII, is formed with OSE-Coll. CI formed with labelled OSE-Coll or OSE-OC probes can be competed by non-labelled sequences from MMP-13 or osteocalcin thereby demonstrating that the proteins interacting with the MMP-13 and osteocalcin promoter are very similar. CII formed with OSE-Coll can be competed by non-labelled OSE-Coll and, with somewhat lower eciency, by the OSE-OC probe. CI and CII could not be competed by an unrelated probe containing the AP-1 binding site (TRE), and vice-versa, the speci®c shift obtained with the TRE probe could not be competed by any of the OSE containing probes.
To demonstrate speci®city of binding of the Cbfa/ Runt proteins, we used a mutant of the CCACA binding motif (mutation m1: CCACA to GAACA, Figure 3a ) which has been shown to abolish protein/ DNA interaction of Cbfa/Runt proteins to the osteocalcin OSE-2 element (Georoy et al., 1995) . Figure 3c shows that m1OSE-OC does not compete for complex formation on OSE-OC and OSE-Coll probes (lanes 8 ± 10 and lanes 18 ± 20). However, introduction of this mutation in the MMP-13 sequence (m1OSE-Coll; sequence in Figure 3a) is not sucient to abolish competition of binding (lanes 5 ± 7 Figure 3 The MMP-13 and osteocalcin promoters share homologous osteoblast-speci®c element (OSE) recognized by members of the Cbfa/Runt transcription factors. (a) Schematic illustration of the promoter regions from the MMP-13 gene (top; Schorpp et al., 1995) and osteocalcin gene (bottom; Ducy and Karsenty, 1995) , with the location of the consensus binding motifs. OSE1, OSE2: osteoblast-speci®c elements 1 and 2 de®ned in the osteocalcin promoter. OSE2 contains a consensus sequence CCACA for binding of Cbfa/Runt transcription factors. The DNA sequence of the OSE element in the MMP-13 promoter is listed (OSE-Coll) and shows a high degree of homology with the OSE2 consensus sequence in osteocalcin promoter (OSE-OC). Dierences between both sequences are indicated by dots in the MMP-13 OSE sequence. Mutated versions of MMP-13 (Coll) and osteocalcin (OC) OSE sequences (m1OSE-Coll, m2OSE-Coll and m1OSE-OC) used for competition in EMSA experiments, are also listed, mutated nucleotides are marked with bold letters. TRE: AP-1 binding site; PEA3 : recognition sequence of Ets proteins. (b) Nuclear extracts from ROS 17/2.8 cells were incubated with radioactively labelled OSE-Coll, OSE-OC or TRE and analysed by electrophoretic mobility shift assays (EMSA). For competition experiments non labelled oligonucleotides were used in 10, 25 and 75 molar excess to the labelled probe (lane 2 ± 4, 6 ± 8, 10 ± 11, 14 ± 19 and 21 ± 24). CI and CII are the OSE-speci®c complexes I and II. NS is a nonspeci®c complex that can be competed only at very high concentrations of speci®c competitors containing the OSE consensus sequence. (c) CI and CII speci®c complexes on OSE-Coll and OSE-OC were each competed with wild type OSE-Coll and OSE-OC respectively. Competition was reduced or abolished by introducing point mutations in the OSE consensus sequences (see Figure 3a for corresponding mutations). (d) Radioactively labelled oligonucleotides, OSE-Coll and OSE-OC, were incubated with nuclear extracts of ROS 17.2/8 cells and protein/DNA complexes were resolved by EMSA as described in (b). The gel was UV irradiated to cross-link DNA bound proteins with the radioactively labelled probe. Protein-DNA complexes of interest (CI and CII) were excised and transferred onto 10% SDS ± PAGE to separate the cross-linked complexes. Arrows show the localization of the 80 kDa and the 60 kDa cross-linked complexes and lanes 15 ± 17). Competition activity is completely lost only upon introduction of additional mutations in the second CCACA consensus sequence of the collagenase probe (lanes 21 ± 23; m2OSE-Coll mutations in Figure 3a ). These data strongly suggest that the OSE sequences in the osteocalcin and MMP-13 promoter are recognized by members of the Cbfa/Runt family of transcription factors and that two adjacent CCACA motives are involved in binding to the MMP-13 promoter.
To demonstrate unequivocally the importance of Cbfa/Runt proteins in PTH-mediated induction of the MMP-13 promoter, we analysed a mutant of the 7663/+29 promoter fragment (m2OSE-Coll) containing point mutations that completely abolish protein binding to the OSE element (Figure 3a and c) . Transient transfections into UMR 106 osteosarcoma cells (Figure 4a ) showed that this 7663/+29 m2OSE-CAT construct exhibited low basal activity similar to the wild type 7663/+29 Coll-CAT construct but was almost completely unresponsive to PTH (1.2+0.2-fold activation) whereas the wild type construct was induced by PTH. Under these conditions the 7663/ +29 and 7500/+63 MMP-13 promoter constructs were activated 3.3 (+0.2) and 3.7 (+0.3)-fold, respectively, in the presence of PTH (Figure 4a and data not shown). These data demonstrate the absolute requirement for Cbfa/Runt protein binding to the OSE element for PTH-dependent activation of the MMP-13 promoter.
To identify the members of the Cbfa/Runt protein family involved in CI and CII binding and activation of the MMP-13 promoter by PTH we performed UV cross-linking analysis of the proteins forming complexes on the MMP-13 and osteocalcin sequences. Protein/DNA complexes were resolved on nondenaturing gels ( Figure 3b ) followed by UV irradiation of the gel. Complexes were localized by autoradiography, excised from the gel and transferred to a denaturing SDS polyacrylamide gel. The apparent molecular weight of the major band forming CI on the MMP-13 and osteocalcin sequences was approximately 80 kDa, in addition a minor band of approximately 60 kDa is detectable. By deduction with the molecular weight of the cross-linked DNA probe (approximately 15 kDa), the apparent molecular weight of the complexed factors are 65 kDa and 45 kDa, respectively. The molecular weight of the protein in the prominent protein/DNA complex (65 kDa) is in agreement with the size of a recently identi®ed splice variant of a member of the Cbfa/Runt family, Cbfa1, which is speci®cally expressed in osteoblasts (Ducy et al., 1997) . The minor complex is likely to be generated by the Cbfa2 protein, also known as PEBP2aB, which was originally identi®ed in lymphoid cells (Bae et al., 1993) . Moreover we have found both Cbfa1 and Cbfa2 to be expressed in UMR 106 cells using a RT ± PCR and sequencing of the ampli®ed products (data not shown). Interestingly, DNA bound proteins forming CI and CII on the collagenase sequence are indistinguishable after migration of the cross-linked products on a denaturing gel. CI is possibly formed by binding of one protein molecule to either one of the CCACA sequences of the MMP-13 or the CCACA sequence seen in the osteocalcin promoter, whereas binding to both CCACA motives in the MMP-13 sequence on either DNA strand maybe responsible for the reduced electrophoretic mobility of CII.
The OSE site is responsible for transactivation of the MMP-13 promoter by Cbfa1 and Cbfa2
Having obtained strong evidence that Cbfa1 and Cbfa2 are able to bind to a cis-acting element required for activation of the MMP-13 promoter in osteosarcoma cells, we wanted to con®rm OSE-speci®c transcriptional activation of the promoter upon co-transfection of expression vectors encoding Cbfa1 and Cbfa2. We therefore ®rst isolated cDNA sequences of cbfa1 and cbfa2 genes (Porte, Teurich and Angel, unpublished) Figure 4 The OSE site is essential for PTH inducibility of the MMP-13 promoter and mediates transactivation by Cbfa/Runt proteins. (a) Induction of wild type and mutant MMP-13 promoter CAT constructs by PTH. UMR 106 cells were transiently transfected with 5 mg CAT constructs containing the wild type 7663/+29 MMP-13 promoter region, 7663/+29 Coll-CAT, or the same promoter region containing m2 point mutations in the OSE site, 7663/+29 m2OSE-Coll-CAT, (for base pair exchange see Figure 3a ). RSV-CAT construct was used as a positive control for transfection eciency and speci®city of the PTH response. Twenty-four hours following transfection, cells were washed and further grown for 24 h in medium containing 0.5% FCS. Cells were subsequently treated with 10 78 M PTH, harvested after 48 h and assayed for CAT activity. (b) OSEspeci®c transactivation of the MMP-13 promoter by Cbfa/Runt proteins. GM637 human ®broblasts were transiently transfected with 5 mg of either 7663/+29 Coll-CAT or 7663/+29 m2OSE-Coll-CAT reporter constructs, together with 5 mg of the empty mammalian expression vector (RSV-0) or RSV vectors encoding Cbfa1 or Cbfa2. Twenty-four hours after transfection the cells were harvested to be assayed for CAT activity. Results presented in a and b are representative autoradiographies from at least three independent experiments from a UMR106 rat osteosarcoma cDNA library. These sequences were introduced into a mammalian expression vector containing the LTR of Rous Sarcoma Virus (Angel et al., 1988) and were cotransfected into GM637 human ®broblasts (which do not express detectable levels of Cbfa1 but signi®cant basal levels of Fos and Jun proteins; data not shown) together with wild type 7663/+29 Coll-CAT or mutated 7663/+29 m2OSE Coll-CAT reporter plasmids. As shown in Figure 4b Cbfa1 induced more than 100-fold higher activity of the wild type promoter but only minor activation of the mutant promoter. Cbfa2 also strongly activated the MMP-13 promoter depending on the presence of a functional OSE sequence, albeit with lower eciency compared to Cbfa1. These data show that the element necessary to trigger PTH-speci®c activation of the MMP-13 promoter also mediates transactivation by Cbfa1 and Cbfa2 proteins.
Factors binding to the TRE and the OSE, AP-1 (c-Fos) and Cbfa1, are required for full MMP-13 expression in vivo during mouse embryonic development
Having established a critical role for AP-1 and Cbfa/ Runt proteins in the regulation of MMP-13 promoter activity in tissue culture cells, we wanted to con®rm these data in vivo using c-fos and cbfa1 knockout mice (Wang et al., 1992; Otto et al., 1997) . We and others have previously shown that during mouse embryonic development expression of MMP-13 is restricted to hypertrophic chondrocytes and osteoblasts Mattot et al., 1995) . The onset of expression at day 14.5 d.p.c. (day post coitum) is strictly associated with intramembranous and endochondral bone formation, but not; a process that critically depends on PTH or PTH-related peptide (PTHrP) as shown by the analysis of PTHrP receptor knockout mice (Lanske et al., 1996) .
When we measured MMP-13 expression at dierent stages of development by Northern blot analysis of RNA from total embryos at stage 14.5 d.p.c., the level of MMP-13 transcripts in embryos lacking c-fos is greatly reduced compared to wild type embryos of the same litter (Figure 5a ). These data show that at the onset of MMP-13 expression in embryonic development, the presence of c-Fos is absolutely required. At later stages, such as 16.5 and 18.5 d.p.c. the dierences in MMP-13 expression between wild type and c-fos
embryos is less severe, presumably due to partial compensation of c-fos de®ciency by other members of the Fos family of proteins. Reduced MMP-13 expression was also seen by in situ hybridization of sections from 16.5 d.p.c wild type and mutant embryos, e.g. in the dorsal part of the ribs and the cranial vertebrae (Figure 5b ) which are one of the ®rst ossi®cation centres in the mouse embryo.
When we analysed wild type and cbfa1 de®cient embryos from the same litter at stage 15.5 d.p.c. by in situ hybridization, MMP-13 expression was detectable in the ossi®cation centres of the dorsal ribs and the cranial vertebrae in wild type but not in the cbfa1 7/7 embryos ( Figure 5c ).These data suggest that c-fos and cbfa1 genes are required for MMP-13 expression in vivo supporting our data obtained in tissue culture cells. This would imply that both factors play a pivotal role in the activation of MMP-13 transcription in cells of the chondro/osteogenic lineage in response to hormones, such as PTH, which regulate bone metabolism.
The DNA binding activity of AP-1, but not Cbfa/Runt proteins, is increased in response to PTH We next wanted to identify the mechanism of how Cbfa1/Runt and c-Fos/AP-1 proteins modulate expression of the MMP-13 promoter in response to PTH. One possibility to amplify transcription is to enhance protein binding to the appropriate recognition sequence in the promoter region of a target gene. When we prepared nuclear extracts from untreated UMR 106 cells and from cells treated with TPA or PTH for varying time periods, binding to the AP-1 site was seen to be low in untreated cells but greatly enhanced upon stimulation by TPA or PTH (Figure 6 ). Maximal levels are reached within 2 h. This can be explained by strong activation of c-fos and c-jun transcription within 30 min followed by accumulation of newly synthesized Fos and Jun proteins ; and data not shown). In contrast, signi®cant binding to the Cbfa1/Runt binding element, OSE, was already detectable in untreated cells but neither PTH nor TPA increased DNA binding activity. These data show that AP-1 and Cbfa/Runt proteins are aected dierently in response to PTH (and TPA): while expression of AP-1 subunits, in particular c-Fos and c-Jun, are increased leading to enhanced DNA binding activity, this event cannot account for the critical role of Cbfa/Runt proteins in PTH-dependent activation of the MMP-13 promoter.
Discussion
Expression of mouse interstitial collagenase (collagenase-3; MMP-13) has been found to be restricted to hypertrophic chondrocytes and osteoblasts in areas of bone formation and remodelling both during embryogenesis and in adult mice Mattot et Figure 6 PTH induces binding of AP-1 to the TRE motif whereas CI and CII are constitutively bound to the OSE of the MMP-13 promoter. UMR 106 cells were starved for 24 h in 0.5% foetal calf serum and subsequently treated with TPA (100 ng/ml) or PTH (10 78 M) for either 2 or 4 h. Cell extracts were prepared and analysed by EMSA. Gel retardation assays were performed using either the AP-1 binding site (TRE, upper panel) or the Runt/Cbfa recognition sequence (OSE, lower panel) of the MMP-13 promoter al., 1995). We show in this study for the ®rst time that expression of MMP-13 is rapidly activated in osteoblasts cells in vivo upon injection of parathyroid hormone, a major regulator of bone remodelling and calcium homeostasis. Based on its unique substrate speci®city and ability to cleave collagens type I, II, and III, the major components of bone, MMP-13 induction is likely to play an important role in PTH-dependent bone resorption. In vivo activation of MMP-13 described here provides functional con®rmation from previous studies on induction of this gene by PTH in primary osteoblast cultures or in cell lines derived from osteosarcomas ( Figure 1) (Heath et al., 1984; .
To elucidate the mechanisms involved in PTHinduced expression of MMP-13, we have analysed the promoter region of this gene in two osteosarcoma cell lines, ROS 17/2.8 and UMR 106. We have identi®ed a cis-acting element located between positions 7139 and 7129 that is required for PTH-dependent induction. Its sequence shares a high degree of homology with an element in the osteocalcin (OC) gene originally described as Osteoblast Speci®c Element 2, OSE2 , which was subsequently identi®ed to be speci®cally recognized by members of the Cbfa/Runt family of transcription factors (Ducy et al., 1997) . These proteins are characterized by the highly conserved RUNT domain of 128 amino acids which is responsible for speci®c DNA-binding of the Runt protein a monomer to a 5'-PuCCPuCA-3' recognition sequence (Kamachi et al., 1990) , and for its interaction with a b cofactor which enhances DNA binding of the a unit and the overall transcriptional activity without interacting directly with DNA (Ogawa et al., 1993a) .
We provide dierent lines of evidence for binding to, and regulation of the MMP-13 promoter by Cbfa/ Runt proteins: (i) protein binding of nuclear factors to the MMP-13 sequence in vitro is eciently competed by the corresponding sequences from the osteocalcin promoter; vice versa binding to the osteocalcin promoter is competed by the MMP-13 sequence; (ii) speci®c point mutations known to interfere with Cbfa/Runt binding to the osteocalcin promoter Georoy et al., 1995) , when introduced in one copy of the CCACA motifs of the element in the MMP-13 promoter reduce protein binding. Mutation of both adjacent CCACA sequences completely eliminates protein/ DNA interaction. (iii) UV cross-linking analysis revealed a major complex generated by a protein with an apparent molecular weight of 65 kDa which is in good agreement with the size of a recently identi®ed splice variant of Cbfa1, which exhibits osteoblast-speci®c expression (Ducy, et al., 1997; Komori et al., 1997; Otto et al., 1997) . In addition, a minor complex is observed which may be due to binding of the Cbfa2 protein, also known as PEBP2aB/AML1 (Bae et al., 1993; Georoy et al., 1995; Miyoshi et al., 1995) . Preincubation of cellular extracts with a Cbfa1-speci®c antiserum (Porte, Strand and Angel, unpublished) greatly reduced in vitro binding to the OSE element (Porte and Angel, unpublished). We were able to clone both Cbfa1 and Cbfa2 cDNAs from the osteosarcoma cells used in our studies. Exogenously overexpressed Cbfa1 and, to a lesser extent, Cbfa2 are very potent transactivators of the wild type MMP-13 promoter but not of the mutant version containing point mutations in the region required for PTH inducibility and protein binding in vitro.
Recently, cbfa1 knockout mice have been generated (Komori et al., 1997; Otto et al., 1997) . In these mice both intramembraneous and endochondral ossi®cation is completely blocked due to a loss of osteoblast dierentiation thereby identifying this transcription factor as a master regulator of bone formation. When we compared MMP-13 expression in wild type and cbfa1 7/7 embryos at stage 15.5 d.p.c. (day post coitum) no expression was detectable in the mutant mice, suggesting that Cbfa1 plays a critical role in triggering MMP-13 expression in vivo. However, MMP-13 is expressed at late stages of dierentiation of chondrocytes and osteoblasts during embryogenesis Tuckermann and Angel, unpublished) . Therefore, more likely, the lack of expression in cbfa1 de®cient mice is due to the absence of osteoblasts (Komori et al., 1997; Otto et al., 1997) , the major source of MMP-13 expression. The expression of MMP-13 and other marker genes of bone tissue, such as alkaline phosphatase and osteocalcin, does not overlap. Moreover osteocalcin, which is expressed at later stages of osteoblast dierentiation compared to MMP-13 (Tuckermann and Angel, unpublished data), is likely to be regulated directly by Cbfa1/Runt proteins. Therefore, none of the aforementioned genes could be used as markers to indicate the presence of the speci®c compartment of dierentiating osteoblasts which express MMP-13. To unequivocally con®rm the requirement of Cbfa/Runt proteins for PTH-dependent MMP-13 expression in vivo, transgenic mice harbouring wild type and OSE-mutant MMP-13 promoter constructs in the genome would have to be analysed for PTH-dependent induction.
Cbfa1 was originally described as Polyoma Enhancer Binding Protein 2 alpha A, PEBP2aA, which was shown to interact with the Polyoma enhancer element A. Protein puri®cation and cDNA cloning revealed that it represents a shorter splice variant of Cbfa1 (Ogawa et al., 1993b) . On this A element the PEBP2aA binding site cooperates with an AP-1 binding site (originally described as PEA1; Kryszke et al., 1987) , to mediate full induction of polyoma enhancer by activated Ha-Ras (Satake et al., 1988) . Both Cbfa/Runt proteins and AP-1 are also required for PTH-dependent induction of the MMP-13 promoter. Deletion or point mutation of either one of the OSE or TRE binding sites eliminates PTH inducibility of the promoter. The mechanisms of functional synergism are still unclear. Based on our in vitro binding studies the mechanisms by which Cbfa/Runt and AP-1 aect MMP-13 promoter activity appear to be dierent. High constitutive Cbfa/Runt DNA binding activity is detectable in untreated cells which is not aected by PTH treatment. In agreement with this ®nding, we did not detect dierences in the level of Cbfa transcripts within 4 h of PTH treatment (Teurich and Angel, unpublished) . In contrast, under these conditions DNA binding of AP-1 is greatly enhanced, due to increased transcription of the cjun and c-fos genes (Clohisy et al., 1992) , followed by enhanced de novo protein synthesis. Accordingly, in the presence of an inhibitor of protein synthesis, PTH-dependent induction of MMP-13 is strongly reduced . Clearly, the presence of c-Fos and c-Jun proteins is critical for regulation of MMP-13 both in vivo and in vitro, as demonstrated by its reduced expression in c-fos 7/7 embryos ( Figure  5) , and the decrease in induction by growth factors, cytokines, TPA and UV irradiation in ®broblasts derived from c-fos and c-jun knockout mice (Hu et al., 1994; Schreiber et al., 1995; Kolbus, Schreiber, Wagner and Angel, unpublished) . However, increased expression and DNA binding of c-Fos and c-Jun proteins by PTH is not sucient for activation of the MMP-13 promoter. It is well accepted that in addition to DNA binding, post-translational modi®cations, particularly changes in the phosphorylation pattern, are required for Fos and Jun to act as transcriptional activators (Minden and Karin, 1997) . PTH is a very potent inducer of cAMP-dependent PKA and induction of c-fos is mediated by this pathway involving phosphorylation of CREB which binds on a CRE responsive element in the c-fos promoter (Pearman et al., 1996) . Although PTH has been found to activate PKC most eects on gene regulation can be blocked by inhibitors of the PKA pathway (Evans et al., 1996; Yang and Gerstenfeld, 1996) . While protein kinases regulating the transactivation function of c-Fos have not been de®ned conclusively, members of the MAP kinase family, Erk1/2 and, in particular, the Jun-N-terminal kinases, JNKs (Minden and Karin, 1997), but not PKA (Smeal et al., 1994) , regulate c-Jun's transactivation potential. Therefore, it is reasonable to assume that, despite transcriptional activation of the c-jun and c-fos genes, synthesized c-Fos and cJun may not be activated by hyperphosphorylation. Hyperphosphorylation of c-Jun's transactivation domain which was detected by Western blot using a phospho-speci®c antibody that speci®cally recognizes c-Jun phosphorylated at serine-63, was observed only in cells treated with TPA and UV, but not in PTH treated cells (Teurich and Angel, unpublished) . In agreement with this ®nding, when we analysed transactivation by chimeras composed of the transactivation domain of c-Jun or c-Fos fused to a Gal4 DNA binding region we observed enhanced transcription of a Gal4-dependent reporter by TPA and alkylating agents (the most potent activators of the Erk1/2 and JNKs, respectively; van Dam et al., 1995; Minden and Karin, 1997) but not by PTH. In addition, we did not detect induction of JNK activity in response to PTH (data not shown). In contrast, strong activators of PKC, such as TPA, eciently induce post-translational modi®cation of c-Jun (and most likely c-Fos) to allow transcriptional activation of the MMP-13 promoter independently from the presence of Cbfa/Runt proteins.
How do Cbfa/Runt proteins contribute to PTHdependent transactivation? Promoter occupation of Cbfa/Runt proteins in unstimulated cells may keep the promoter in an`open' state to ensure accessibility of the AP-1 binding site and rapid induction upon binding of newly synthesized Fos/Jun. It is also possible that Cbfa/Runt proteins directly participate in transcriptional activation of the collagenase-3 promoter. In the absence of transcriptional activation of the corresponding cbfa genes PTH-dependent phosphorylation of pre-existing molecules have to be postulated. Interestingly, the C-terminal half of Cbfa1/PEBP2aA and Cbfa2/ PEPBaB are particularly enriched in proline and serine/threonine residues containing potential MAP kinase phosphorylation sites (Tanaka et al., 1996) . However, when we fused the complete C-terminus of Cbfa2 to the Gal4 DNA binding domain and tested the chimeric protein for its ability to activate transcription, only very low transactivation potential was detectable, in agreement with previous ®ndings (Zaiman and Lenz, 1996) . The transactivation was also hardly aected by PTH, TPA or alkylating agents (Teurich and Angel, unpublished) showing that neither members of the MAP kinase family, nor PTH-induced PKA target the C-terminal half of Cbfa/Runt proteins. However, it is still possible that the N-terminal half of Cbfa2 and Cbfa1, in particular the sequences that are only present in the osteoblast-speci®c splice variant of Cbfa1, contain a transactivation domain whose activity is regulated by upstream signalling pathways.
On the human MMP-1 promoter which contains an AP-1 but no Cbfa/Runt binding sites (Angel et al., 1987a) functional synergism between AP-1 and Ets proteins binding to the PEA3 motif have been described for the induction by oncoproteins (Gutman and Wasylyk, 1990) . A PEA3 binding site is also present in the murine MMP-13 promoter (Schorpp et al., 1995) . However, this type of cross-talk appears not be involved in PTH-dependent regulation of MMP-13 because the promoter construct harbouring functional AP-1 and PEA3 sites but containing point mutations in the Cbfa/Runt binding site is not inducible by PTH. In addition, the promoter fragment containing the OSE and PEA3 binding site fused to the thymidine kinase promoter does not mediate a PTH response. Mutation of the PEA3 site in the rat MMP-13 promoter, which shows a high degree of homology to its murine and human counterparts, does not aect inducibility by PTH (Partridge, personal communication) . Likewise the PEA3 site of the human collagenase-3 gene seems not to play an important role in the regulation of promoter activity (Pendas et al., 1997) .
Using c-fos transgenic mice, MMP-13 was identi®ed as the ®rst example of an AP-1-regulated target gene in vivo (Gack et al., 1994) . However, ubiquitous overexpression of c-Fos results in tissue-speci®c induction of MMP-13, the most prominent site of expression being in osteoblasts in the bone. It is tempting to speculate that, similar to PTH induction, MMP-13 transactivation by enhanced levels of c-Fos depends on Cbfa1/Runt proteins and can only be observed in cells or tissues expressing these proteins. Interestingly, the sites of c-Fos-induced overexpression of MMP-13 correlate with the sites of phenotypic alterations, such as the formation of bone tumours, induced by long-term overexpression of c-Fos. In light of the cooperative action of AP-1 and Cbfa/Runt proteins in transcriptional activation of the polyoma enhancer by Ha-Ras, it will be interesting to determine, whether the presence of Cbfa/Runt proteins, in addition to their physiological role in PTH-dependent bone remodelling and calcium homeostasis may enable c-Fos to execute its transformation potential in bone cells.
Material and methods

Animals
Six-month-old male C57BL/6J mice (BRL, Switzerland) were housed under serum pathogen free conditions, under incandescent light for 12 h a day. All animals had free access to food (Purina Chow 5008) and water and were handled in accordance with the principles and guidelines established by the National Institutes of Health.
Administration of parathyroid hormone was carried out as described by Pollock et al. (1996) , with the following modi®cations. Mice were anaesthetized with Ketanest (100 mg/kg; Bayer, Leverkusen) and Rompun (0.2 mg/kg; Parke-Davis, Berlin). Subsequently 50 ml 0.9% sodium chloride as a control, or 20 mg rat PTH (1 ± 34; Sigma) dissolved in 50 ml 0.9% sodium chloride were injected subcutaneously over the midline of the parietal bone. Animals awakened 1 h after injection and were sacri®ced 8 h after injection. Calvaria were prepared and liberated from non-osseous tissues and homogenized under liquid nitrogen using a mortar and a pestle. Total RNA was prepared according to standard protocols (Chomczynski and Sacchi, 1987) and MMP-13 expression was analysed by RT ± PCR.
Preparation of mouse embryos for sections was performed as described Otto et al., 1997) .
Cell culture
Rat osteosarcoma cells ROS 17/2.8 were grown in Ham's F12 medium supplemented with 10% foetal calf serum. UMR-106 (NTCC) rat osteosarcoma cells and GM637 human ®broblasts were grown in DMEM (Gibco) supplemented with 10% foetal calf serum. All cells were treated with either 10 78 M rat PTH-fragment-(1 ± 34) or 100 ng/ml 12-O-tetradecanoyl-phorbol-13-acetate (TPA, Sigma). Total RNA from tissue culture cells was prepared according to standard protocols (Chomczynski and Sacchi, 1987) .
Primary mouse osteoblastic cells were isolated from calvaria of 10 day postnatal mice according to the protocol described by Shalhoub et al. (1992) .
Analysis of gene expression
Reverse transcription reactions of the RT ± PCR analysis were performed using RT Expand TM Reverse Transcriptase (Boehringer Mannheim), 18 mer oligo(dT) primer and 0.5 mg total RNA, followed by PCR ampli®cation of a 541 bp MMP-13 cDNA fragment using the following primers: antisense primer Coll24: 5'-GGTCACAC-TTCTCTGGT-3' (exon 5) and sense primer Coll29: 5'-GTTTTCCCTAGAACACTC-3' (exon 2). The PCR reaction was performed for 30 cycles using an annealing temperature of 558C. For standardization of the amount of cDNA, b-actin speci®c transcripts were measured by PCR using the primers: 5'-TGGACAGTGAGGCCAG-GATG-3' (antisense) and 5'-TCGTGCGTGACATCAAA GAG-3' (sense). PCR was carried out using an annealing temperature of 558C for 20 cycles yielding a 429 bp fragment.
For Northern Blot analysis total RNA was separated on a denaturing agarose gel. After blotting, transferred RNA were hybridized with a 32 P labelled fragment of murine MMP-13 cDNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as described (Gack et al., 1994) .
Expression vectors and reporter genes
For construction of MMP-13 CAT reporter plasmids, a 0.7 kb PstI/NcoI fragment of the murine MMP-13 promoter spanning the region from 7663 to +32 was cloned (Schorpp et al., 1995) . A SalI restriction site was introduced by PCR to eliminate the start site of translation (+30/+32) and the 0.7 kb PstI/SalI fragment was introduced into pBLCAT3 (Luckow and Schutz, 1987) yielding 7663/+29 Coll-CAT. 7500/+29 was generated by digestion of the plasmid 7663/+29 with HindIII followed by religation. To generate the construct 766/ +29 Coll-CAT, 7663/+29 was digested with HpaI and HindIII linkers were added. The DNA fragment was then digested with HindIII and SalI. The appropriate 0.1 kb HindIII/SalI fragment was inserted into HindIII/SalI opened pBLCAT3 plasmid. To generate the 7500/766 tk-CAT construct, 7663/+29 Coll-CAT was digested with HpaI and BamHI linkers were added.The DNA fragment was digested with BamHI and HindIII yielding a 0.5 kb HindIII/BamHI fragment that was inserted into the HindIII/BamHI digested pBLCAT2 plasmid (Luckow and Schutz, 1987) . Plasmid 7663/+29 m2OSE-Coll-CAT was constructed by site directed mutagenesis using the QuickChange TM Site-Directed Mutagenesis Kit (Amersham) according to the manufacture's guidelines using plasmid 7663/+29 Coll-CAT as template. Appropriate cloning and introduction of point mutations was con®rmed by sequencing.
The cDNA clones encoding Cbfa1 and Cbfa2 were isolated by screening a lambda gt-11 cDNA library of rat osteosarcoma cells (Quinn et al., 1990 ) using a 0.3 kb cDNA probe encoding the Runt homology region. This probe was isolated by RT ± PCR using degenerate oligonucleotides derived from the Runt domain of murine Cbfa2 (Bae et al., 1993) . Additional cbfa1 and cbfa2 sequences were isolated by RT ± PCR from UMR106 cells (Porte, Teurich and Angel, in preparation) . Clones containing the complete coding region of Cbfa1 and Cbfa2 were introduced into a mammalian expression vector by replacing the c-jun sequences in the RSV-c-Jun plasmid (Angel et al., 1988) .
Transient transfections
ROS 17.2/8 cells and UMR 106 cells were transiently transfected by the calcium phosphate method as described by Angel et al. (1987a) . The transfection mix was left on the cells overnight and then removed by washing twice with PBS followed by the addition of fresh culture medium to the cells. For PTH or TPA treatment, the medium was replaced after 24 h culture by fresh medium containing 0.5% FCS. Twenty-four hours later rat PTH fragment 1 ± 34 (Sigma) or 12-O-tetradecanoyl-phorbol-13-acetate (TPA) was added at ®nal concentrations of 10 78 M and 100 ng/ml, respectively. For measurement of CAT activity, cell extracts were prepared 48 h post-stimulation and analysed as described by Angel et al. (1987a) .
In RNase protection assays the levels of CAT mRNA transcripts were determined. RNA was prepared 12 h after treatment and analysed by using a tk-CAT-speci®c riboprobe as described previously (Angel et al. 1987b) .
Electrophoretic mobility shift assay (EMSA) and UV cross-link Nuclear extracts from ROS 17/2.8 cells were prepared according to the protocol described (Dignam et al., 1983) . Protein concentration was determined using the`protein bio assay solution' (Biorad). EMSA were performed with 10 ± 20 mg protein from nuclear extracts incubated with 25 fmole of 32 P radiolabelled OSE or TRE oligonucleotides as described previously (Schorpp et al., 1995) . The sequences of the used probes are: wild type OSE-Coll: 5'-AG-CTGATTCTGCCACAAACCACACTT-3' and 5'-AGC-TAAGTGTGGTTTGTGGCAGAATC-3'; m1OSE-Coll: 5'-AGCTGATTCTGCCA CAAAGAACACTT-3' and 5'-AGCTAAGTGTTCTTTGTGGCAGAATC -3', m2OSE-Coll: 5'-AGCTGATTCTGGTACCAAGAACACTT-3' and 5'-AGCTAAGTGTTCTTGGTACCAGAATC-3'; wild type OSE -OC:
5' -AGCTGCTGCAATCACCAAGAACAG-CA -3' and 5' -AGCTTGCTGTGGTTGGTGATTGCA-GC-3'; m1OSE-OC : 5'-AGCTGCTGCAATCACCAAGAA-CAGCA-3' and 5'-AGCTTGCTGTTCTTGGTGATTG-CAGC-3'. The TRE probe, 5'-AGCTAAAGTGGTGACT-CATCACTAT-3' and 5'-AGCTATAGTGATGAGTCAC-CACTTT-3', corresponds to the region 754 and 734 of the murine MMP-13 promoter (Schorpp et al., 1995) .
For cross-linking DNA and bound proteins by UV an EMSA experiment was performed using 20 ± 30 mg of nuclear protein extract. After electrophoresis the gel was left on one glass plate and irradiated with UV light (15 kJ/m 2 at 254 nm). The wet gel was autoradiographed for 3 ± 4 h at 48C to identify the positions of the protein/DNA complexes. Complexes of interest were excised from the gel, boiled for 5 min in loading buer (60 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue, 2.5% b-mercaptoethanol) and separated by SDS ± PAGE.
In situ hybridization
Paran embedded sections of paraformaldehyde ®xed mouse embryos (15.5 d.p.c., 16.5 d.p.c.) . were cut at 6 mm and mounted on 3-aminopropyl-triethoxysilane (TESPA)-coated slides. The sections were subjected to in situ hybridization as described . Deparaffinized sections were pre-treated with proteinase K and deacetylated. The generation of 35 S-UTP-labelled sense and antisense probes of MMP-13 for in situ hybridization was performed as described . The pre-treated sections were hybridized with the labelled probe (1 ± 2610 5 c.p.m./ml) in a humid chamber overnight at 508C followed by extensive washing at high-stringency. The slides were dried, dipped in autoradiography emulsion (NTB2, Kodak, Rochester, NY, USA), and exposed for 10 days at 48C for autoradiography. After development of the glass slides, the sections were stained with hematoxylin (0.1%, Sigma) and eosin (1%) and mounted. Visualization was carried out using a DMLB Microscope (Leica) with a 3CCD camera (Hitachi).
